Joseph Garcia
Partner | Vancouver
Vancouver: 604-631-3307

Joseph's practice focuses on corporate finance and mergers and acquisitions. He advises public and private companies, investment dealers, venture capital and private equity funds and acts as independent counsel to boards of directors. Joseph has extensive experience advising on all types of merger and acquisition and corporate finance transactions including public and private equity and debt financings, take-over and issuer bids, share and asset acquisitions and divestitures, and regulatory and stock exchange compliance work.

Prior to his career in law, Joseph worked in corporate finance with a national investment bank and in clinical research with a multinational pharmaceutical company.

Joseph provides legal services through Joseph Garcia Law Corporation.

SELECT EXPERIENCE

Recent representative transactions include advising:

  • Neovasc in connection with its US$37.5-million underwritten offering of series A and series B units (comprised of a combination of common shares or series D pre-funded warrants, series C units and series A, B, C and F warrants to purchase common shares) and concurrent US$27.8-million private placement of notes and series E warrants to purchase common shares

  • The underwriters in connection with the C$11.5-million prospectus offering of units by Oncolytics Biotech

  • Zymeworks in connection with its US$64-million initial public offering of common shares and listing on the Toronto Stock Exchange and the New York Stock Exchange

  • Helius Medical in connection with its C$12.5-million MJDS prospectus offering of common shares

  • Volkswagen Financial Services AG in connection with its acquisition of PayByPhone

  • Neovasc in connection with the sale of its tissue business and concurrent private placement to Boston Scientific for US$75-million

  • Weyerhaeuser in connection with the sale of its Cellulose Fibers pulp mill in Alberta to International Paper

  • Response Biomedical in connection with its going-private transaction

  • ESSA in connection with its US$10-million term loan from Silicon Valley Bank

  • The underwriters in connection with the US$25.9-million prospectus offering of common shares by Xenon Pharmaceuticals and the concurrent US$8.6-million secondary offering

  • 3D Signatures in connection with the closing of its qualifying transaction on the TSX Venture Exchange and concurrent C$5.45-million private placement of common shares

  • The underwriters in connection with the exchange offer of DFC Finance's US$800-million outstanding principal amount of 10.5 per cent senior secured notes due 2020

  • Opko Health in connection with its acquisition of Transition Therapeutics for US$60-million in common shares

  • Cardiome Pharma in connection with its US$34.5-million MJDS prospectus offering of common shares

  • SciVac in connection with its acquisition of VBI Vaccines for US$92.1-million in shares

  • Helius Medical in connection with its C$10.2-million prospectus offering and its listing on the Toronto Stock Exchange

  • Private company in connection with its US$25-million Series C preferred share financing

  • ESSA Pharma in connection with its US$15-million private placement of units

  • Zymeworks in connection with its US$61.5-million mezzanine preferred share financing

  • Zymeworks in connection with its equity investment and optional merger agreement with Kairos Therapeutics

  • Cardiome Pharma in connection with its up to US$20-million prospectus offering

  • CPI Card Group in connection with its US$150-million initial public offering of common shares, concurrent US$22.5-million secondary offering, and listing on the Toronto Stock Exchange and the NASDAQ Global Select Market

  • Cardiome Pharma in connection with its US$23-million prospectus offering of common shares

  • VRG Capital in connection with its backing of a management buy-out of Jones Brown, and the subsequent acquisition of Pearson Dunn Insurance

  • UrtheCast in connection with the C$100-million acquisition of the Earth Observation business of Elecnor and its concurrent prospectus offering of C$100-million of subscription receipts

  • SciVac in connection with its reverse take-over transaction of Levon Resources with an aggregate transaction value of C$356-million and its listing on the Toronto Stock Exchange

  • The underwriters in connection with the US$55.2-million prospectus offering of common shares by Trillium Therapeutics

  • Urthecast in connection with its C$17.25-million prospectus offering of common shares

  • Neovasc in connection with its US$74.9-million MJDS prospectus offering of common shares and the concurrent US$11.9 secondary prospectus offering

  • Zymeworks in connection with its C$27-million private placement and the expansion of its strategic collaboration with Eli Lilly and Company

  • The underwriters in connection with the US$41.4-million initial public offering of common shares by Xenon Pharmaceuticals and its listing on the NASDAQ Global Select Market

  • Neovasc in connection with its C$25-million prospectus offering of common shares

  • The underwriters in connection with the US$60-million prospectus offering of common shares by Tekmira Pharmaceuticals

  • The underwriters in connection with the US$53-million initial public offering of common shares by Aquinox Pharmaceuticals and its listing on the NASDAQ Global Select Market

  • Cardiome Pharma in connection with its C$15-million prospectus offering of common shares and the concurrent C$15-million secondary prospectus offering

  • Cardiome Pharma in connection with its C$30-million at-the-market prospectus offering of common shares

  • The agent in connection with the US$52-million private placement of units of Aurinia Pharmaceuticals

  • Aequus Pharmaceuticals in connection with its private placement, prospectus filing and direct listing on the TSX Venture Exchange

  • ESSA Pharma in connection with its private placement, prospectus filing and direct listing on the TSX Venture Exchange

  • iCo Therapeutics in connection with its C$6.75-million prospectus offering of common shares

  • UrtheCast in connection with its C$10-million prospectus offering of common shares

  • Cardiome Pharma in connection with its cross-border acquisition of Correvio

  • Response Biomedical in connection with its private placement of subscription receipts

  • GenomeDx Biosciences in connection with its series B preferred share financing

  • Boreal Genomics in connection with its series C preferred share financing

  • UrtheCast in connection with its reverse takeover transaction of Longford Energy, concurrent financing and listing on the Toronto Stock Exchange

  • enGene in connection with its Series A preferred share financing

  • Aspreva Pharmaceuticals in connection with its acquisition by Galenica for US$950-million

  • ID Biomedical in connection with its acquisition by GlaxoSmithKline for C$1.7-billion

AWARDS & RECOGNITION

Joseph recently received the following awards:

  • Canadian Financial & Transactional Attorney of the Year - LMG Life Sciences Awards 2015

  • Visionary Leadership - BIOTECanada Gold Leaf Awards 2015

  • Partner/Advisor of the Year - LifeSciences BC Awards 2015

Joseph is also featured as a leading lawyer in numerous publications including:

  • Chambers Canada: Canada's Leading Lawyers for Business 2018 (Life Sciences)

  • The Best Lawyers in Canada 2018 (Biotechnology, Corporate, Corporate Governance Practice, Mergers & Acquisitions and Securities)

  • The 2017 Lexpert Guide to the Leading US/Canada Cross-Border Corporate Lawyers in Canada (Corporate Finance and Securities)

  • The Canadian Legal Lexpert Directory 2017 (Biotechnology, Corporate Finance & Securities, Corporate Mid-Market, Private Equity and Technology Transactions)

  • Who's Who Legal: Canada 2017 (Life Sciences)

  • LMG Life Sciences: The Definitive Guide to the Leading Life Sciences Firms and Attorneys in North America 2016 (Star Attorney in Canada)

  • Lexpert's Special Edition on Energy, November 2014 (Canada's Leading Energy Lawyers)

  • The Lexpert/American Lawyer Guide to the Leading 500 Lawyers in Canada (2011: Corporate Mid-Market; 2008-2009: Biotechnology)

PUBLICATIONS
Show Past:
Page: 1 of 1       1        Items per page: 25 | 50 | ALL
Co-author: In Search of Capital: A Growing Number of Life Sciences Companies are Choosing to Go Public
BIOTECanada Insights Magazine, pp.54-57, May 2015.
Page: 1 of 1       1        Items per page: 25 | 50 | ALL
PROFESSIONAL APPEARANCES
Page: 1 of 1       1        Items per page: 25 | 50 | ALL
Speaker: IPO-Readiness Panel, Canadian Venture Capital and Private Equity Association 2015
Annual Conference, Vancouver, British Columbia, May 19, 2015.
Speaker: Cross-Border IPO's: Challenges and Opportunities
Advanced Securities Law Course, Continuing Legal Education Society of British Columbia, Vancouver, British Columbia, April 30, 2015.
Page: 1 of 1       1        Items per page: 25 | 50 | ALL